{"disease":{"id":"relapsing-remitting-multiple-sclerosis","name":"Relapsing remitting multiple sclerosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":22,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"dimethyl-fumarate","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecfidera","generic_name":"DIMETHYL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"dimethyl fumarate","quality_score":59,"revenue":"2800","mechanism":"Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system."},{"drug_id":"teriflunomide","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aubagio","generic_name":"TERIFLUNOMIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"dihydroorotate dehydrogenase","drug_class":"Pyrimidine Synthesis Inhibitor [EPC]","quality_score":75,"revenue":"1100","mechanism":"Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS."},{"drug_id":"siponimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"interferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avonex","generic_name":"INTERFERON BETA-1A","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":55,"revenue":"800","mechanism":"Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"peginterferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plegridy","generic_name":"PEGINTERFERON BETA-1A","company_name":"Biogen Idec Inc","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":"800","mechanism":"Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"ozanimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zeposia","generic_name":"OZANIMOD","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":72,"revenue":"800","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"cladribine","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leustatin","generic_name":"CLADRIBINE","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","drug_class":"Purine Antimetabolite [EPC]","quality_score":75,"revenue":"700","mechanism":"Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways."},{"drug_id":"daclizumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"avonex","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avonex","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gilenya","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gilenya","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate lyase 1, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"plegridy","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Plegridy","company_name":"Holy Name Medical Center, Inc.","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"betaseron","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Betaseron","company_name":"University of Medicine and Dentistry of New Jersey","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tecfidera","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tecfidera","company_name":"EMD Serono Research & Development Institute, Inc.","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"laquinimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nerventra","generic_name":"LAQUINIMOD","company_name":"Teva","drug_phase":"discontinued","molecular_target":"","drug_class":"laquinimod","quality_score":null,"revenue":null,"mechanism":"Nerventra works by modulating the immune system to reduce inflammation in the central nervous system."},{"drug_id":"mitozantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mayzent","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"campath","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"interferon-beta-1b","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaseron","generic_name":"INTERFERON BETA-1B","company_name":"Bayer Healthcare Pharms","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta","quality_score":10,"revenue":null,"mechanism":"Betaseron works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"mitoxantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"fingolimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gilenya","generic_name":"FINGOLIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":75,"revenue":null,"mechanism":"Gilenya works by binding to and blocking the S1P1 receptor, preventing immune cells from leaving the lymph nodes and reducing inflammation in the central nervous system."},{"drug_id":"alemtuzumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."}],"pipeline":[],"offLabel":[],"totalMarketed":22,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00493298","title":"Tysabri Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":6620,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT03193866","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","phase":"","overall_status":"COMPLETED","enrollment_count":3526,"lead_sponsor_name":"Karolinska Institutet","has_results":true},{"nct_id":"NCT03302442","title":"Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT00835770","title":"BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1736,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT01797965","title":"Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1501,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT01067521","title":"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1404,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT01930708","title":"A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1114,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01633112","title":"MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1064,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02255656","title":"Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1062,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT01623596","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":881,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT00641537","title":"CLARITY Extension Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":867,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT00078338","title":"Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":764,"lead_sponsor_name":"EMD Serono","has_results":true},{"nct_id":"NCT04688788","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03093324","title":"A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05949580","title":"Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06700343","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":444,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT01051349","title":"Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05758831","title":"RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":386,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT04940065","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","phase":"","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01498887","title":"Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":347,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06526000","title":"Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT05304520","title":"A Study for Tysabri Participant Preference","phase":"","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04225312","title":"Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT00879658","title":"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":297,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02677077","title":"Clinical Disease Activity With Long Term Natalizumab Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT02975349","title":"A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":267,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT04115488","title":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Polpharma Biologics S.A.","has_results":true},{"nct_id":"NCT00745615","title":"An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":257,"lead_sponsor_name":"Teva Pharmaceutical Industries, Ltd.","has_results":true},{"nct_id":"NCT01485003","title":"Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants","phase":"","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01838668","title":"An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06733922","title":"ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07318129","title":"Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Glostrup University Hospital, Copenhagen","has_results":false},{"nct_id":"NCT02525874","title":"Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT04578639","title":"Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":214,"lead_sponsor_name":"Haukeland University Hospital","has_results":false},{"nct_id":"NCT00203021","title":"Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT05811416","title":"A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT00884481","title":"Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS","phase":"","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT02587065","title":"Plegridy Satisfaction Study in Participants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT01943526","title":"Ireland Natalizumab (TYSABRI) Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05123703","title":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":188,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01185821","title":"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07235644","title":"Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT06083753","title":"Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Contineum Therapeutics","has_results":false},{"nct_id":"NCT07497126","title":"The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":169,"lead_sponsor_name":"Antalya Training and Research Hospital","has_results":false},{"nct_id":"NCT05242133","title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Cinnagen","has_results":false},{"nct_id":"NCT04468165","title":"Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region","phase":"","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Hikma Pharmaceuticals LLC","has_results":false},{"nct_id":"NCT04711148","title":"A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}